ResearcherBrooke Army Medical CenterActive in the last 2 years
Alexandra M. Adams
Matched on ORCID iD 0000-0002-0894-1871; OpenAlex author ID A5101979671. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers
Papers 7
- Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. Co-author DOI 10.1002/jso.27466↗
- The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy. Co-author DOI 10.1002/jso.27689↗
- Morbidity and Mortality of Non-pancreatectomy operations for pancreatic cancer: An ACS-NSQIP analysis. Co-author DOI 10.1016/j.amjsurg.2022.08.012↗
- Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12908-z↗
- Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-13758-z↗
- Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. Co-author DOI 10.1245/s10434-022-11800-0↗
- Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/ott.s311661↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniel William Nelson · 6 shared papers, 2021–2024 · strength 1.00
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Timothy J. Vreeland · 6 shared papers, 2021–2024 · strength 1.00
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Elizabeth L. Carpenter · 5 shared papers, 2022–2024 · strength 0.88
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Phillip M. Kemp Bohan · 4 shared papers, 2022–2024 · strength 0.69
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Patrick M. McCarthy · 4 shared papers, 2021–2024 · strength 0.62
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Paper Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. DOI 10.1245/s10434-022-11800-0↗
- Anne E. O’Shea · 4 shared papers, 2021–2024 · strength 0.62
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Paper Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. DOI 10.1245/s10434-022-11800-0↗
- Robert W. Krell · 3 shared papers, 2021–2023 · strength 0.57
- Paper Morbidity and Mortality of Non-pancreatectomy operations for pancreatic cancer: An ACS-NSQIP analysis. DOI 10.1016/j.amjsurg.2022.08.012↗
- Paper Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. DOI 10.1245/s10434-022-11800-0↗
- Paper Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Duct… DOI 10.2147/ott.s311661↗
- Holly V. Spitzer · 2 shared papers, 2023 · strength 0.37
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Franklin A. Valdera · 2 shared papers, 2024 · strength 0.36
- Robert Connor Chick · 2 shared papers, 2022–2024 · strength 0.31
- Bradley Norman Reames · 1 shared paper, 2023 · strength 0.31
- Timothy Eric Newhook · 1 shared paper, 2024 · strength 0.19
- Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.18
- Ching-Wei David Tzeng · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.